Watch Ticker

XORTX Therapeutics Inc. Common Stock

Go to XORTX Therapeutics Inc. Common Stock Website

$0.00

(%)
Live
Previous Close

$

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$7.3 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid met...

Community
  • 0 posts discussing
0

Watchers

0

Visitors

Recent News

CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of March 11, 2024, the Company has received TSX Venture Exchange approval to amend the terms of an aggregate of 1,024,099 outstanding common share purchase warrants (“Warrants”) by amending the exercise price to USD $5.00 per share as follows:

Related tickers: XRTX, XRTX.

Read Full Article

CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models" has been accepted for publication in the peer-reviewed American Journal of Physiology-Renal Physiology and published online April 19, 2024.

Related tickers: XRTX, XRTX.

Read Full Article
Trending Tickers
AMBO

XASE

$1.35
(%)
LASE

XNAS

$2.62
(%)
SMFL

XNAS

$2.70
(%)
BFRG

XNAS

$2.99
(%)
MLGO

XNAS

$0.00
(%)